Treatment, prognostic markers and survival in thymic neuroendocrine tumours. A study from a single tertiary referral centre

Lung Cancer

Volumn 79, Issue 3, 2013, Pages 289-293

  Crona, Joakim ^a   Björklund, Peyman ^a   Welin, Staffan ^a   Kozlovacki, Gordana ^a   Öberg, Kjell ^a   Granberg, Dan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Carcinoid; Chemotherapy; Ki67; Neuroendocrine; Thymic; Thymus; Tumour

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; SORAFENIB; STREPTOZOCIN; TAXANE DERIVATIVE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; THYMIC NEUROENDOCRINE TUMOR; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NEUROENDOCRINE; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM COMPOUNDS; PROGNOSIS; REFERRAL AND CONSULTATION; SWEDEN; TERTIARY CARE CENTERS; THYMUS GLAND; THYMUS NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84873188000     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.12.001     Document Type: Article

References (27)

1. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., et al. One hundred years after " carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26(18):3063-3072.
2. Rosai J., Higa E. Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor. Clinicopathologic study of 8 cases. Cancer 1972, 29(4):1061-1074.
3. Filosso P.L., Actis Dato G.M., Ruffini E., Bretti S., Ozzello F., Mancuso M. Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): report of a successful case and review of the literature. J Thorac Cardiovasc Surg 2004, 127(4):1215-1219.
4. Tiffet O., Nicholson A.G., Ladas G., Sheppard M.N., Goldstraw P. A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus. Chest 2003, 124(1):141-146.
5. Falchetti A., Marini F., Brandi M.L. Multiple endocrine neoplasia Type 1 1993.
6. Goudet P., Murat A., Cardot-Bauters C., Emy P., Baudin E., du Boullay Choplin H., et al. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg 2009, 33(6):1197-1207.
7. Yano M., Fukai I., Kobayashi Y., Mizuno K., Konishi A., Haneda H., et al. ACTH-secreting thymic carcinoid associated with multiple endocrine neoplasia type 1. Ann Thorac Surg 2006, 81(1):366-368.
8. Boix E., Pico A., Pinedo R., Aranda I., Kovacs K. Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour. Clin Endocrinol (Oxf) 2002, 57(1):131-134.
9. Takagi J., Otake K., Morishita M., Kato H., Nakao N., Yoshikawa K., et al. Multiple endocrine neoplasia type I and Cushing's syndrome due to an aggressive ACTH producing thymic carcinoid. Intern Med 2006, 45(2):81-86.
10. de Montpreville V.T., Macchiarini P., Dulmet E. Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases. J Thorac Cardiovasc Surg 1996, 111(1):134-141.
11. Kale S.B., Saksena D.S., Kole S.D., Agnihotri Y.C. Carcinoid tumors of the thymus. Asian Cardiovasc Thorac Ann 2006, 14(2):e30-e32.
12. Wang D.Y., Chang D.B., Kuo S.H., Yang P.C., Lee Y.C., Hsu H.C., et al. Carcinoid tumours of the thymus. Thorax 1994, 49(4):357-360.
13. Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003, 97(4):934-959.
14. Oberg K., Jelic S. Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):147-149.
15. Moran C.A., Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. Am J Clin Pathol 2000, 114(1):100-110.
16. Gal A.A., Kornstein M.J., Cohen C., Duarte I.G., Miller J.I., Mansour K.A. Neuroendocrine tumors of the thymus: a clinicopathological and prognostic study. Ann Thorac Surg 2001, 72(4):1179-1182.
17. Gaur P., Leary C., Yao J.C. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg 2010, 251(6):1117-1121.
18. Cardillo G., Treggiari S., Paul M.A., Carleo F., De Massimi A.R., Remotti D., et al. Primary neuroendocrine tumours of the thymus: a clinicopathologic and prognostic study in 19 patients. Eur J Cardiothorac Surg 2010, 37(4):814-818.
19. Rindi G., Kloppel G., Alhman H., Caplin M., Couvelard A., de Herder W.W., et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449(4):395-401.
20. Goto K., Kodama T., Matsuno Y., Yokose T., Asamura H., Kamiya N., et al. Clinicopathologic and DNA cytometric analysis of carcinoid tumors of the thymus. Mod Pathol 2001, 14(10):985-994.
21. Fukai I., Masaoka A., Fujii Y., Yamakawa Y., Yokoyama T., Murase T., et al. Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study in 15 patients. Ann Thorac Surg 1999, 67(1):208-211.
22. Granberg D., Wilander E., Oberg K., Skogseid B. Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab 2000, 85(9):3425-3430.
23. Scarpa A., Mantovani W., Capelli P., Beghelli S., Boninsegna L., Bettini R., et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010, 23(6):824-833. Epub 2010 Mar 19.
24. Strosberg J.R., Coppola D., Klimstra D.S., Phan A.T., Kulke M.H., Wiseman G.A., et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010, 39(6):799-800.
25. Moertel C.G., Kvols L.K., O'Connell M.J., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991, 68(2):227-232.
26. Ekeblad S., Sundin A., Janson E.T., Welin S., Granberg D., Kindmark H., et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007, 13(10):2986-2991.
27. Welin S., Sorbye H., Sebjornsen S., Knappskog S., Busch C., Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011.